Navigation Links
Cardium Presents Year-End 2012 Financial Results And Recent Developments
Date:4/5/2013

d Genedexa pilot study represents an important next step forward towards FDA registration of Cardium's advanced DNA biologic wound care product.  Genedexa represents the first product candidate based on the Company's Excellagen product platform and is comprised of the FDA-cleared Excellagen collagen topical gel and an adenovector gene therapy with DNA encoding for PDGF-B protein.  PDGF-B is believed to promote wound healing by directly stimulating cells involved in wound repair and also by eliciting the production of other growth factors.  The Genedexa product candidate, a DNA-based biologic, requires data from clinical studies demonstrating patient safety and efficacy prior to filing for a Biologic License Application (BLA).  The Company may use alternative independent private financings and strategic partners to finance the clinical development of Genedexa and commercialize its LifeAgain platform. 

About CardiumCardium is an asset-based health sciences and regenerative medicine company focused on the acquisition and strategic development of innovative products and businesses with the potential to address significant unmet medical needs and having definable pathways to commercialization, partnering or other economic monetizations. Cardium's current portfolio includes the Tissue Repair Company, Cardium Biologics, and the Company's newly-acquired To Go Brands® nutraceutical business. The Company's lead commercial product, Excellagen® topical gel for wound care management, has received FDA clearance for marketing and sale in the United States.  Cardium's lead clinical development product candidate Generx® is a DNA-based angiogenic biologic intended for the treatment of patients with myocardial ischemia due to coronary artery disease. To Go Brands ® develops, markets and sells dietary supplements through established regional and national r
'/>"/>

SOURCE Cardium Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related medicine technology :

1. Cardium Announces $4.0 Million Preferred Stock Financing And Reports On Exchange Listing Compliance
2. Cardium Receives ISO Certification for Excellagen
3. Cardium Announces Presentaton at The 2013 Cell & Gene Therapy Forum
4. Cardium Presents Third Quarter 2012 Financial Results and Reports on Recent Developments
5. Cardium Announces Excellagen Poster Presentatons At Desert Foot 9th Annual High Risk Diabetic Foot Conference
6. Cardium Presents Second Quarter 2012 Financial Results And Reports On Recent Developments
7. Cardium Announces Plans For Commercializaton Of Excellagen® In The Russian Federation
8. Cardium to Present at Sachs Associates 2012 Science, Partner, and Investment Forum: Gateway for the Global Life Sciences
9. Cardium Announces Agreement With UK-Based Angel Biomedical For Excellagen Supply And Planned European Market Expansion
10. Cardium Exhibiting Its New FDA-Cleared Excellagen® At The 2012 Spring Symposium Of Advanced Wound Care
11. Pharmagen Presents to North Carolina General Assembly at N.C. Bios Legislative Breakfast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... 2015  Amgen (NASDAQ: AMGN ) today ... 2015. Key results include: , Total revenues ... 2014 to $5,370 million, with 6 percent product ... (etanercept), Prolia ® (denosumab), Sensipar ® ... (denosumab). Unfavorable changes in foreign exchange rates ...
(Date:7/30/2015)... China , July 30, 2015 Tianyin ... a pharmaceutical company that specializes in the patented biopharmaceutical, ... pharmaceutical ingredients (API), provided updates regarding the notice it ... LLC (the "Exchange") indicating that the Company was below ... forth in Sections 134 and 1101 of the NYSE ...
(Date:7/30/2015)...  Growth of the U.S. nonprescription market is primarily ... users to the OTC market. Due to an increasingly ... switch activity over the next five years with several ... brands entering the market into existing categories. ... (even those with low to moderate likelihood), the market ...
Breaking Medicine Technology:Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 2Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 3Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 4Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 5Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 6Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 7Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 8Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 9Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 10Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 11Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 12Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 13Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 14Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 15Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 16Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 17Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 18Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 19Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 20Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 21Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 22Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 23TPI Provides Update Regarding Non-Compliance with NYSE MKT Continued Listing Requirements 2Rx-to-OTC Switches -- Game Changers for the U.S. OTC Drugs Market through 2019, Sees Kline 2Rx-to-OTC Switches -- Game Changers for the U.S. OTC Drugs Market through 2019, Sees Kline 3
... CVS Caremark reiterated the company,s support that the U.S. ... approve biogeneric drugs under the Affordable Care Act. The ... Reid, testified before the FDA today during a public ... for biosimilar and interchangeable biological products held at the ...
... 2010 Spectros Corporation presented new clinical results ... Tissue Oximeter at the San Diego Convention Center ... presented during poster sessions entitled "Experimental Circulation: Ischemia ... the American Society of Anesthesiologists (ASA 2010) on ...
Cached Medicine Technology:CVS Caremark Reiterates Support for FDA Implementation of Approval Pathway for Biogeneric Drugs 2Spectros Presents New Clinical Studies Using T-Stat VLS Tissue Oximeter at Anesthesiology 2010 2
(Date:8/1/2015)... ... August 01, 2015 , ... On March 19, 2015 Phil Valentine – the Executive Director ... Appalachian Trail by stepping off Springer Mountain and heading north. Since that day, ... Phil reached Connecticut and was greeted by friends and family. He visited CCAR and ...
(Date:7/31/2015)... ... July 31, 2015 , ... When the weather turned hot and ... new type of sod called Leisure Time(TM) zoysia . It's nicknamed LTZ(TM) for ... commemorate introduction of this new type of sod, Super-Sod is giving away red Adirondack ...
(Date:7/31/2015)... (PRWEB) , ... July 31, 2015 , ... Ticket Down ... is currently going on in Chicago at Grant Park. The festival will end ... of North America to Chicago for the annual Lollapalooza. This unique and unbelievably ...
(Date:7/31/2015)... ... July 31, 2015 , ... ... run by GoodThreads. The store can be accessed by visiting http://www.curemeso.org/store . ... which are customizable. The best part: whenever a product is purchased, the Meso ...
(Date:7/31/2015)... , ... July 31, 2015 , ... There’s no better ... even when it comes time to cook the next meal, making July the most ... by practicing best grilling tips and recipes. , Make the next cookout different than ...
Breaking Medicine News(10 mins):Health News:Connecticut Executive Hikes Appalachian Trail to Raise Awareness About Recovery. 2Health News:Super-Sod Introduces Leisure Time(TM) Zoysia Grass with an Adirondack Chair Promotion 2Health News:Cheap 2015 Lollapalooza Tickets: Ticket Down Slashes Ticket Prices on Lollapalooza Tickets at Grant Park in Chicago for Saturday, August 1st and Sunday, August 2nd 2Health News:Mesothelioma Organization Launches New Store 2Health News:Mesothelioma Organization Launches New Store 3Health News:King Kullen Honors National Hot Dog and Blueberry Month 2Health News:King Kullen Honors National Hot Dog and Blueberry Month 3
... 26 Grand Opening Festivities Will Include Health Education Fair,Tour ... "9 Steps to Optimum,Health", HUNTERSVILLE, N.C., July 16 ... is dedicated to successfully treating,diseases that were previously thought ... level of health, today announced that it will open,the ...
... have developed a new method for reconstructing a cell,s ... the history of the development of cancer. , The ... a cell lineage tree, is shared by many branches ... key to answering many fundamental questions, such as whether ...
... drugs may trigger protein that boosts tumor growth, study finds ... after organ transplants may be the reason why 15 percent ... a higher risk of developing cancer within the next decade. ... diminish the risk, said Harvard researchers reporting in the July ...
... July 16 MDdatacor, Inc., a leader in ... providers, today,announced the appointment of Gregory A. Buchholz ... In this new role, Buchholz will be,responsible for ... will oversee the quality assurance, project management,informatics, data ...
... Family, Inc.,(Nasdaq: AFAM ), a leading regional provider ... established a new senior secured,multi-bank credit facility replacing its ... of the Company,s assets and the,stock of its subsidiaries., ... J.P. Morgan Securities, Inc., The new facility provides ...
... Dental, Burkhart Dental and Goetze Dental Bring Over, 300 Years Experience, ... ... U.S. Regions, LIVINGSTON, N.J., July 16 ... injection technologies, today announced that leading independent,dental supply companies -- Benco ...
Cached Medicine News:Health News:North Carolina's Center For Advanced Medicine & Clinical Research Celebrates Opening of New LKN Medical Spa and Rejuvenation Center 2Health News:North Carolina's Center For Advanced Medicine & Clinical Research Celebrates Opening of New LKN Medical Spa and Rejuvenation Center 3Health News:Weizmann Institute scientists' new technique gets to the root of cancer 2Health News:Weizmann Institute scientists' new technique gets to the root of cancer 3Health News:Researchers Find Link Between Organ Transplants, Cancer 2Health News:MDdatacor Names Gregory Buchholz Chief Operating Officer 2Health News:Almost Family Secures $75 Million Revolving Credit Facility 2Health News:Almost Family Secures $75 Million Revolving Credit Facility 3Health News:Milestone Scientific Expands Domestic Sales Network With Addition of Three New Dental Distributors 2Health News:Milestone Scientific Expands Domestic Sales Network With Addition of Three New Dental Distributors 3Health News:Milestone Scientific Expands Domestic Sales Network With Addition of Three New Dental Distributors 4
The ImagingPlanet 55 mm Surgical Microscope Adapter. Superior optical quality and precise engineering make this 55mm focal length adapter an excellent decision for use with your Zeiss surgical micro...
... Capture Archive Manage ... Images. ,Introducing Optronics DVMR- office, ... system designed for the physician's ... from a variety of high-resolution ...
... Optronics QuantiFIRE represents the latest innovation ... scientific grade CCD imaging for microscopy. ... Monochrome CCD camera developed exclusively for ... fluoresence or NIR imaging applications where ...
... This system is the most ... world. Developed in the USA after ... safety, and complete precision with maximum ... exfoliation. It is superior to traditional ...
Medicine Products: